

# Prenatal exposure to arsenic and lung function in children from the New Hampshire Birth Cohort Study

Antonio J. Signes-Pastor<sup>1</sup>, Pablo Martinez-Camblor<sup>2</sup>, Emily Baker<sup>3</sup>, Juliette Madan<sup>1,4</sup>, Margaret F. Guill<sup>4</sup>, Margaret R. Karagas<sup>1</sup>.

<sup>1</sup>Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, <sup>2</sup>Biomedical Data Science Department, Geisel School of Medicine, Dartmouth College, Lebanon, NH, <sup>3</sup>Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH. <sup>4</sup>Department of Pediatrics, Geisel School of Medicine, Dartmouth College, Lebanon, NH.

\* Corresponding author. *E-mail address:* [margaret.r.karagas@dartmouth.edu](mailto:margaret.r.karagas@dartmouth.edu) (M.R. Karagas).

## Abstract

Prenatal arsenic exposure is associated with an increased risk of lung cancer along with multiple non-carcinogenic outcomes, including respiratory diseases in arsenic-contaminated areas. Limited epidemiologic data exist on whether *in utero* arsenic exposure influences lung development and subsequent respiratory health. We investigated the association between gestational arsenic exposure and childhood lung function in the New Hampshire Birth Cohort Study. Urinary arsenic speciation including inorganic arsenic (iAs), monomethylarsonic acid (MMA), dimethylarsinic acid (DMA) and arsenobetaine was measured in maternal urine samples collected during pregnancy and spirometry was performed in offspring at a median age of 7.4 years. Forced vital capacity (FVC), forced expiratory volume in the first second of exhalation (FEV1), and forced expiratory flow between 25% and 75% of FVC (FEF25-75) standardized z-scores were assessed in linear models as dependent variables with the log<sub>2</sub>-transformed summation of urinary arsenic species ( $\Sigma\text{As} = \text{iAs} + \text{MMA} + \text{DMA}$ ) corrected for specific gravity as an independent variable and with adjustment for maternal smoking status, children's age, sex and height. Among the 358 children in the study, a doubling of  $\Sigma\text{As}$  was associated with a -0.08 ( $\beta$ ) decrease in FVC z-scores (95% confidence interval (CI) from -0.14 to -0.01) and -0.10 ( $\beta$ ) (95% CI from -0.18 to -0.02) decrease in FEV1 z-scores. The inverse association appeared stronger among those mothers with lower secondary methylation index (urinary DMA/MMA), especially among girls. No association was observed for FEF25-75 z-scores. Our results suggest that gestation arsenic exposure at levels relevant to the general US population during the vulnerable period of lung formation may adversely affect lung function in childhood.

**Keyword:** children; lung capacity; arsenic speciation; gestational exposure; spirometry.

## 1. Introduction

Arsenic is an element ubiquitously present in our water, food and air from both natural and anthropogenic activities. Human exposure to arsenic comes through inhalation, dermal absorption, and ingestion (Al osman et al., 2019). Consumption of contaminated drinking water is the predominant exposure pathway (IARC, 2012). However, ingestion of arsenic from food is also a significant source of exposure of growing concern, particularly for populations non-occupationally exposed and with access to drinking water with relatively low arsenic levels (Nachman et al., 2018).

Inorganic arsenic (iAs), including arsenite (AsIII) and arsenate (AsV), is a well-established toxic chemical form, and its exposure is of major public health concern (ATSDR, 2013; Shih et al., 2019). Chronic iAs exposure is associated with an increased risk of different cancers including skin, lung, and bladder among others (IARC, 2012; Smith et al., 2006). Exposure to iAs is also associated with other health effects among populations exposed to highly contaminated drinking water, in particular, respiratory outcomes (Mazumder, 2007; Olivas-Calderón et al., 2015; Parvez et al., 2013; Ramsey et al., 2013; Recio-Vega et al., 2015; Sanchez et al., 2016; Von Ehrenstein et al., 2005). In arsenic-contaminated areas, fetal and early childhood exposure has been associated with increased risk of lower respiratory tract infections and prevalence of respiratory symptoms (e.g., shortness of breath, chronic cough, and wheeze) during childhood, as well as reduced lung function and mortality from lung cancer, bronchiectasis, and tuberculosis in adulthood (Dauphiné et al., 2011; Rahman et al., 2011; Raqib et al., 2009; Smith et al., 2006, 2011, 2013). However, the possibility that even relatively low iAs exposure levels early in life may alter both childhood and adulthood respiratory health requires further epidemiologic and mechanistic investigations (Farzan et al., 2016; Hsu et al., 2020; Miller and Marty, 2010; Postma et al., 2015; Steinmaus et al., 2016).

Respiratory abnormalities can be identified from patterns of pulmonary function measured by spirometry such as obstructive or restrictive airflow (Camargo et al., 2014; Martinez-Pitre et al., 2020; Miller and Marty, 2010). A recently published meta-analysis and systematic review of studies mainly among highly exposed adult populations reported an association between arsenic exposure and respiratory health, especially in relation to restrictive lung function (Sanchez et al., 2016, 2018). Among school-age children consuming contaminated water in rural Bangladesh, gestational arsenic exposure also related to airflow restrictive patterns with a decrease in forced vital capacity (FVC) and forced expiratory volume in the first second of exhalation (FEV1) (Ahmed et al., 2017). Further, arsenic-induced alterations in inflammatory biomarkers in children in Mexico were related to the development of restrictive lung diseases (Olivas-Calderón et al., 2015; Recio-Vega et al., 2015). In animal models, arsenic in drinking water during pregnancy increased resistance in the peripheral airway and markers of tissue stiffness in the offspring (Lantz et al., 2009; Ramsey et al., 2013).

Ingested iAs is metabolized in the liver through a multistep process via the one-carbon metabolism cycle that results in the formation of monomethylarsonic acid (MMA) followed by dimethylarsinic acid (DMA) that are primarily excreted in urine within a few days (Antonelli et al., 2014; Challenger, 1951; Tseng, 2009). Thus, the sum of iAs and its methylated arsenic species (MMA and DMA) in urine is used as a biomarker of ingested iAs exposure (Powers et al., 2019; Signes-Pastor et al., 2017a). Methylation of iAs is an important mechanism in the metabolism of iAs, and the ratio between urinary MMA/iAs and

DMA/MMA can be used as markers of iAs methylation capacity (McCarty et al., 2007; Niedzwiecki et al., 2014). Arsenic easily crosses the placenta and enters the fetus such that maternal blood levels positively correlate with infant cord blood levels (Concha et al., 1998; Hall et al., 2007; Ramsey et al., 2013). Therefore, we investigated arsenic exposure during pregnancy in a general US population, and evaluated maternal arsenic methylation capacity in relation to the pulmonary function among children in the New Hampshire Birth Cohort study (NHBCS) to test the hypothesis that fetal exposure to arsenic affects lung development ultimately impacting lung function in school-aged children.

## 2. Methods

### **2.1. Study population**

Our study comprised infants enrolled in the NHBCS, a longitudinal pregnancy cohort designed to examine the impacts of toxicants in drinking water and diet on maternal–child health. Since 2009, the NHBCS recruited pregnant women 18–45 years of age at approximately 24–28 weeks of gestation from prenatal clinics in the rural state of New Hampshire. Eligibility criteria include English literacy, the use of a private, unregulated water system at home (e.g., private well), not planning to move during pregnancy and a singleton birth as described previously (Gilbert-Diamond et al., 2016; Karagas et al., 2016; Signes-Pastor et al., 2020). The Committee for the Protection of Human Subjects at Dartmouth College approved this study, and all participants provided written informed consent.

### **2.2. Samples collection**

Mothers provided a spot urinary samples at approximately 24–28 weeks of gestation during the enrollment period in polyethylene sterile containers. Samples were processed and frozen at -80°C within 24 hours until analysis (Karagas et al., 2016). We also collected household tap water samples at enrollment to analyze their arsenic concentrations (Gilbert-Diamond et al., 2016).

### **2.3. Laboratory Analysis**

Urine-specific gravity was analyzed using a handheld refractometer with automatic temperature compensation (PAL-10S; ATAGO Co Ltd). The urine samples were thoroughly thawed, centrifuged, and the supernatant pipetted into 0.6 ml vials before arsenic speciation analysis. The Trace Element Analysis Core at Dartmouth College carried out arsenic speciation using anion exchange chromatography inductively coupled plasma mass spectrometry (HPLC-ICP-MS) (Signes-Pastor et al., 2020). It was an Agilent LC 1260 equipped with a Thermo AS7, 2 x 250 mm column and a Thermo AG7, 2 x 50 mm guard column interfaced with an Agilent 8900 ICP-MS in oxygen reaction cell mode to remove polyatomic interferences. We measured concentrations of urinary AsIII, AsV, MMA, DMA, and arsenobetaine (AsB). A gradient mobile phase was prepared starting with 200 mM ammonium carbonate. Authentic standards from SPEX Certiprep and Sigma-Aldrich were used to calibrate the arsenic concentrations under each chromatographic peak. Several NIST reference materials 2669 level I and level II were also analyzed in each analysis batch, with recoveries close to 100%. The arsenic species limit of detection (LOD) ranged from 0.01 to 0.39 µg/L across batches. We calculated the LODs as the mean of the blank concentrations plus three times their standard deviation multiplied by the dilution factor. We did not

observe urinary DMA concentrations below the LOD. However, there were 149 (41.6%), 76 (21.2%), 83 (23.2%), and 83 (23.2%) observations with concentrations of AsIII, AsV, MMA, and AsB below the LOD. We applied the value of LOD/ $\sqrt{2}$  when concentrations were <LOD (Lubin et al., 2004). Total arsenic in tap water samples was measured with the Agilent 8900 ICP-MS in direct solution acquisition mode with a LOD of 0.04  $\mu\text{g/L}$ .

#### **2.4. Lung function**

Children's lung function was assessed with spirometry along with ascertainment of children's age, height and weight. The spirometry was performed according to the American Thoracic Society and European Respiratory Society criteria in a single testing session by trained personnel (Beydon et al., 2007; Crapo et al., 1995). Trained staff performed pulmonary function testing and pre-testing education. All flow-volume curves were *post hoc* inspected for quality assurance by a pediatric pulmonologist (MG). The highest measurement obtained of each lung function parameter from a series of three technically acceptable flow-volume curves was used for statistical analysis (Miller et al., 2005). The FVC, FEV1 and forced expiratory flow between 25% and 75% of FVC (FEF25-75) were each measured. In addition, we calculated the ratio FEV1/FVC and the standardized z-scored for FVC, FEV1, and FEF25-75 (Culver et al., 2017; Harris et al., 2018). We computed the z-scores as the absolute values minus predictive values divided by standard deviation of predictive values.

#### **2.5. Covariates**

We selected *a priori* based on previous studies and directed acyclic graphs using the DAGitty software: maternal smoking status during pregnancy (never smoker, former smoker, and current smoker), maternal highest attained level of education (less than 11<sup>th</sup> grade or high school graduate or equivalent, junior college graduate or some college or technical school, college graduate, and any post-graduate schooling) were collected from self-administered questionnaires, maternal age at enrollment (years, continuous) and maternal body mass index (BMI) calculated using maternal pre-pregnancy weight combined with height ( $\text{kg/m}^2$ , continuous) were collected from prenatal medical records, and child's sex from the delivery medical records. As mentioned, child's age (years, continuous), weight (kilograms, continuous), and height at spirometry test (centimeters, continuous) were assessed at the visit (Farzan et al., 2016; Powers et al., 2019; Stick et al., 1996).

#### **2.6. Statistical analysis**

We examined urinary iAs (AsIII + AsV), MMA, DMA and the summation of the species ( $\Sigma\text{As} = \text{iAs} + \text{MMA} + \text{DMA}$ ) concentrations. They were positively skewed and thus were  $\log_2$ -transformed for the analyses. Spirometry parameters showed symmetric distributions. For the main statistical analysis, we followed a case-complete approach. A total of 410 children (excluding 9 with missing spirometry parameters) had complete data from the pulmonary function test. We excluded children with spirometry parameter values out of the acceptable range ( $n = 2$ ), without maternal urinary arsenic species concentrations ( $n = 2$ ) and specific gravity ( $n = 21$ ) leaving 385 participants. Our final dataset contained 358 maternal-child pairs after excluding those with missing values in maternal smoking status ( $n = 27$ ) (Figure S1). We evaluated maternal urinary methylation capacity during pregnancy by calculating their primary

methylation (PMI = urinary MMA/iAs) and secondary methylation indices (SMI = urinary DMA/MMA) (Niedzwiecki et al., 2014).

We examined the associations between exposures and the outcomes of interest using scatterplots with moving average lowess curves. Graphical inspection showed little evidence of non-linear association between maternal urinary log<sub>2</sub>-transformed arsenic concentrations and children's spirometry parameters. Therefore, we conducted linear regression analyses to evaluate the association between *in utero* arsenic exposure and children's standardized z-score spirometry parameters. The FVC, FEV1, and FEF25-75 z-scores were fitted in the models as dependent variables and the log<sub>2</sub>-transformed specific gravity-corrected urinary arsenic species concentrations as independent variable adjusting for potentially confounding factors including maternal smoking status, children's age, sex and height. Further analyses included FEV1/FVC as the dependent variable. We performed additional models stratified by maternal methylation capacity using the median PMI and SMI as cutoff values and by sex. As sensitivity analyses to assess the possibility of residual confounding, we ran models restricted to non-smoker mothers and included additional adjustment for maternal age at enrollment, which was weakly correlated with urinary DMA, FEV1 and FVC z-scores (Spearman's  $\rho = 0.1$ ) but unrelated iAs, MMA,  $\Sigma$ As and the other outcomes, and child's weight, which correlated with FEV1 z-score and FEV1/FVC (Spearman's  $\rho = 0.2$ ) but not associated with iAs, MMA, DMA,  $\Sigma$ As or other outcomes (data not shown). A threshold of  $\alpha = 0.05$  was used to define associations as statistically significant. We used the R version 4.0 to conduct all statistical analyses and graphics (R Code Team, 2015).

### 3. Results

The median maternal age of enrollment was 30.7 years, and about 90% were not smokers ( $n = 322$ ). Maternal medians urinary  $\Sigma$ As, iAs, MMA, DMA, and AsB were 3.6  $\mu\text{g/L}$ , 0.3  $\mu\text{g/L}$ , 0.3  $\mu\text{g/L}$ , 2.9  $\mu\text{g/L}$ , and 0.8  $\mu\text{g/L}$ , respectively. A total of 46% of children were boys ( $n = 167$ ). The spirometry test was performed at children's median age of 7.4 years with a median weight and height of 125.0 cm and 25.6 kg, respectively (**Table 1**). About 80% and 74% of participants with household water arsenic concentrations ( $n = 350$ ) had water concentrations  $<10 \mu\text{g/L}$  ( $n = 288$ ) and  $<5 \mu\text{g/L}$  ( $n = 259$ ), respectively. The value of 10  $\mu\text{g/L}$  is the World Health Organization guideline and the United States Environmental Protection Agency standard for drinking water (US EPA, 2012; WHO, 2011), and the 5  $\mu\text{g/L}$  is the recently established maximum public water arsenic level in the state of New Hampshire (NHDES, 2019).

A doubling of maternal urinary  $\Sigma$ As was associated with a decrease of -0.08 ( $\beta$ ) in FVC z-score with a 95% confidence interval (CI) ranging from -0.14 to -0.01. We also observed a reduced FVC z-score with maternal urinary iAs and DMA ( $\beta = -0.06$ , 95% CI from -0.12 to -0.01;  $\beta = -0.07$ , 95% CI from -0.14 to -0.01, respectively). We found a borderline statistically significant association between urinary MMA concentrations and FVC z-score ( $\beta = -0.05$ , 95% CI from -0.10 to 0.00). Similarly, a doubling of urinary  $\Sigma$ As, iAs, MMA, and DMA related to a reduction in FEV1 z-scores ( $\beta = -0.10$ , 95% CI from -0.18 to -0.02;  $\beta = -0.09$ , 95% CI from -0.16 to -0.02;  $\beta = -0.07$ , 95% CI from -0.12 to -0.01; and  $\beta = -0.08$ , 95% CI from -0.17 to -0.01, respectively). The inverse associations between maternal urinary arsenic and FVC and FEV1 z-scores were stronger among participants with lower SMI. For example, a doubling of urinary

MMA related to a reduction in FVC and FEV1 z-scores of  $\beta = -0.18$  and 95% CI from -0.29 to -0.07 and  $\beta = -0.20$  and 95% CI from -0.33 to -0.06, respectively (**Figure 1**). We observed comparable findings when including additional potential confounding factors in the models such as maternal age of enrollment and children's weight (**Figure S2**). We had similar results when restricting our analyses to mothers never smoker (**Table S2**). Findings from the stratified analysis by sex were also persistent but suggested somewhat stronger associations among girls (**Figure S3**); however, in the overall regression models, the interaction term between child's sex and maternal urinary arsenic concentrations did not reach statistical significance with a range of *p*-values from 0.281 to 0.933 (**Table S2**). We did not observe any clear association between maternal urinary arsenic species concentrations and children's lung function z-scores in any of the other conducted models using FEV1/FVC as the dependent variable (**Table S1**).

#### 4. Discussion

In this study, we found that maternal gestational urinary arsenic concentrations at levels common to the general US population were associated with reduced children's FVC and FEV1 z-scores. We also found evidence of potential modification of these effects by maternal methylation capacity and sex-specific effects.

A study from Mexico with 358 children of 6-12 years of age exposed to arsenic mainly from drinking water (mean 152.1  $\mu\text{g/L}$ ) starting *in utero* and until early childhood and with an average urinary arsenic of 141.2  $\mu\text{g/L}$ , reported a reduced FVC and FEV1. Higher urinary arsenic concentrations were found among children with restrictive spirometry patterns (prevalence of 57%) compared with children with normal patterns (Recio-Vega et al., 2015). The MINIMat cohort in rural Bangladesh investigated the association between maternal urinary  $\Sigma\text{As}$  during pregnancy with an average (range) of 76 (2, 2063)  $\mu\text{g/L}$  and lung function in 540 9-year-old children. They reported an inverse association with FVC and FEV1 in volumetric units ( $\beta = -12$ ; 95% CI from -22 to -1.5 ml, and  $\beta = -12$ ; 95% CI from -22 to -1.9 ml, respectively) (Ahmed et al., 2017). In our study population, we did not observe an association between arsenic exposure and FEV1/FVC but a reduced FVC and FEV1 supporting potentially restrictive effects on pulmonary airflow (Sanchez et al., 2018). While our analysis was based on z-scores so are not directly comparable, our exposure levels being far lower than Bangladesh resulted in smaller effect sizes compared to those found in children from the MINIMat cohort (Ahmed et al., 2017).

Arsenic can disrupt the highly complex signaling between embryonic lung tissue of mesenchymal and endodermal origin and can permanently alter lung structure and function in experimental studies (Miller and Marty, 2010). In mice, arsenic exposure during pregnancy at relatively low levels (10 and 100  $\mu\text{g/L}$ ) from drinking water caused impaired postnatal lung function in particular abnormal stiffening of the lung parenchyma in the offspring, along with impeded development of the distal airways and alveolar tissue (Ramsey et al., 2013). In humans, the lung formation starts with the development of the lung bud from the fetal foregut at 6 weeks' gestation. Airway generation down to the bronchiolar level are formed by the end of the first trimester of pregnancy. During childhood airways continue to grow, then lung size increases with chest wall growth until adolescence, reaches a plateau at 20-25 years of age and then declines (Merkus et al., 1996). Failure to reach a normal plateau affects airway function (Camargo et al., 2014; Lange et al., 2015; Postma et al., 2015). A prior study suggested sex-specific differences in

1 response to arsenic exposure, such as male mice offspring more susceptible to the effects of arsenic on  
2 lung growth and performance than females. However, these lung mechanics alterations were not  
3 persistent in adulthood (Ramsey et al., 2013). Our study shows that girls may be more susceptible to the  
4 toxic effects of arsenic during gestation on lung function, which could relate to an increased  
5 overexpression of genes related to estrogen (Shen et al., 2007). We need further studies to understand  
6 the mechanisms by which effects of arsenic may manifest differently in males and females.

7 In humans, there is large inter-individual variation in methylation capacity of iAs and is characterized by  
8 the formation of DMA (60-70%) and MMA (10-20%) excreted in urine along with unmetabolized iAs (10-  
9 30%) (Signes-Pastor et al., 2017b; Vahter, 2002). Altered profiles of urinary arsenic species in urine  
10 appear to reflect differences in the efficacy of iAs metabolism and are genetically driven (Agusa et al.,  
11 2011). There is evidence that this influences individual susceptibility to the adverse effects of iAs  
12 including risks of skin, bladder, and lung cancer among highly exposed populations (Chen et al., 2003;  
13 López-Carrillo et al., 2014; Steinmaus et al., 2006; Yu et al., 2000). In this study, gestational arsenic  
14 exposure related to a reduced lung function in the offspring of women with decreased iAs methylation  
15 capacity. On average, we observed a 2.6-fold decrease in FVC and FEV1 z-scores in children whose  
16 mother had a low SMI compared to those with a high SMI. An earlier study from the MINIMat cohort  
17 also found a stronger inverse association between maternal urinary arsenic and children's FVC and FEV1  
18 among those whose mother had higher percentages of MMA and lower percentages of DMA (Ahmed et  
19 al., 2017).

20 There are limitations in our study. Our study population was healthy overall, and the prevalence of  
21 airflow obstruction and restrictive patterns was low. Indeed, <2% of children would be classified with  
22 clinical airflow obstruction ( $FEV1/FVC < 0.70$ ) or restrictive ( $FVC < 80\%$  predicted together with  $FEV1/FVC$   
23  $\geq 0.70$ ) patterns (Powers et al., 2019). We adjusted our primary models for known risk factors selected  
24 from a minimally sufficient set of potential confounders; however, residual confounding is still possible.  
25 Therefore, we performed sensitive analysis adding in the models maternal age at enrollment and  
26 children's weight. The results were consistent with those from the main analyses. AsB is a putative non-  
27 toxic form of arsenic excreted in the urine unchanged related to fish/seafood consumption, which may  
28 cause exposure misclassification of iAs when total urinary arsenic serves as exposure biomarker (Navas-  
29 Acien et al., 2011; Signes-Pastor, et al., 2017a, 2019). In our study population, urinary AsB  
30 concentrations with a median  $< 1 \mu\text{g/L}$  suggest a limited fish/seafood consumption. However, we  
31 measured urinary arsenic speciation and calculated the summation of iAs, MMA and DMA excluding AsB  
32 ( $\Sigma\text{As}$ ), but did not consider urinary DMA from direct ingestion or from the metabolism of other  
33 organoselenical compounds (e.g., arsenosugars and arsenolipids) also related to fish/seafood intake  
34 (Molin et al., 2015). We used single maternal urine samples; however, urinary arsenic concentrations  
35 show temporal stability with consistent patterns of exposure (Signes-Pastor et al., 2021). Our findings  
36 suggest sex-related differences in the strength of the effects of gestational arsenic exposure. However,  
37 in the sex-stratified analyses we had limited statistical precision, and thus the results need to be  
38 interpreted carefully. Also, it is important to recognize that our study did not consider postnatal arsenic  
39 exposure, which is expected to be dominated by ingestion of household water and food (Signes-Pastor  
40 et al., 2018). Thus, additional studies are needed with repeated postnatal measurements of arsenic  
41 exposure.



Our study indicates an association between arsenic exposure at relatively low levels during pregnancy and reduced lung function in childhood that may be important later in life. Additional prospective research is needed to confirm our observations, including potential sex-related and metabolic differences. Our findings support efforts to minimize gestational iAs exposure to reduce the risks of adverse effects on lung formation during this vulnerable window to prevent the potential onset of respiratory diseases throughout the lifespan.

## Credit authorship contribution statement

Antonio J. Signes-Pastor (**AS**): Methodology, formal statistical analysis, visualization, writing, and review; Pablo Martinez-Camblor (**PM**): Methodology, support statistical analysis and review; Emily Baker (**EB**): Methodology and review; Juliette Madan (**JM**): Methodology and review; Margaret F. Guill (**MG**): Spirometry quality assurance and review; Margaret R. Karagas (**MK**): Conceptualization, methodology, and review.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Funding sources

**AS** and **MK** are funded in part by the following projects P01ES022832, RD83544201, R25CA134286, P42ES007373, and 5UH3OD023275. **AS** is also funded by CIDEAGENT/2020/050.

## References

- Agusa, T., Fujihara, J., Takeshita, H., Iwata, H., 2011. Individual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms. <https://doi.org/10.3390/ijms12042351>
- Ahmed, S., Akhtar, E., Roy, A., Von Ehrenstein, O.S., Vahter, M., Wagatsuma, Y., Raqib, R., 2017. Arsenic exposure alters lung function and airway inflammation in children: A cohort study in rural Bangladesh. *Environment International*. <https://doi.org/10.1016/j.envint.2017.01.014>
- Al osman, M., Yang, F., Massey, I.Y., 2019. Exposure routes and health effects of heavy metals on children. *BioMetals* 32, 563–573. <https://doi.org/10.1007/s10534-019-00193-5>
- Antonelli, R., Shao, K., Thomas, D.J., Sams, R., Cowden, J., 2014. AS3MT, GSTO, and PNP polymorphisms: Impact on arsenic methylation and implications for disease susceptibility. *Environmental Research* 132, 156–167. <https://doi.org/10.1016/j.envres.2014.03.012>
- ATSDR, 2013. Agency for Toxic Substances and Disease Registry (ATSDR), in: *Health Care Policy and Politics a to Z*. <https://doi.org/10.4135/9781452240121.n18>
- Beydon, N., Davis, S.D., Lombardi, E., Allen, J.L., Arets, H.G.M., Aurora, P., Bisgaard, H., Davis, G.M., Ducharme, F.M., Eigen, H., Gappa, M., Gaultier, C., Gustafsson, P.M., Hall, G.L., Hantos, Z., Healy, M.J.R., Jones, M.H., Klug, B., Carlsen, K.C.L., McKenzie, S.A., Marchal, F., Mayer, O.H., Merkus, P.J.F.M., Morris,

1 M.G., Oostveen, E., Pillow, J.J., Seddon, P.C., Silverman, M., Sly, P.D., Stocks, J., Tepper, R.S., Viložni, D.,  
2 Wilson, N.M., 2007. An Official American Thoracic Society/European Respiratory Society Statement:  
3 Pulmonary function testing in preschool children. *American Journal of Respiratory and Critical Care*  
4 *Medicine* 175, 1304–1345. <https://doi.org/10.1164/rccm.200605-642ST>

5 Camargo, C.A., Budinger, G.R., Escobar, G.J., Hansel, N.N., Hanson, C.K., Huffnagle, G.B., Buist, A.S.,  
6 2014. Promotion of lung health: NHLBI workshop on the primary prevention of chronic lung diseases.  
7 *Annals of the American Thoracic Society* 11. <https://doi.org/10.1513/AnnalsATS.201312-451LD>

8 Challenger, F., 1951. Biological methylation, in: *Advances in Enzymology and Related Subjects of*  
9 *Biochemistry*. wiley, pp. 429–491. <https://doi.org/10.1002/9780470122570.ch8>

10 Chen, Y.C., Su, H.J.J., Guo, Y.L.L., Hsueh, Y.M., Smith, T.J., Ryan, L.M., Lee, M.S., Christiani, D.C., 2003.  
11 Arsenic methylation and bladder cancer risk in Taiwan. *Cancer Causes and Control*.  
12 <https://doi.org/10.1023/A:1023905900171>

13 Concha, G., Vogler, G., Lezcano, D., Nermell, B., Vahter, M., 1998. Exposure to inorganic arsenic  
14 metabolites during early human development. <https://doi.org/10.1006/toxs.1998.2486>

15 Crapo, O., Hankinson, J.L., Irvin, C., MacIntyre, N.R., Voter, K.Z., Wise, R.A., Graham, B., O'Donnell, C.,  
16 Paoletti, P., Roca, J., Veigi, G., 1995. Standardization of spirometry: 1994 Update.  
17 <https://doi.org/10.1164/ajrccm.152.3.7663792>

18 Culver, B.H., Graham, B.L., Coates, A.L., Wanger, J., Berry, C.E., Clarke, P.K., Hallstrand, T.S., Hankinson,  
19 J.L., Kaminsky, D.A., MacIntyre, N.R., McCormack, M.C., Rosenfeld, M., Stanojevic, S., Weiner, D.J., 2017.  
20 Recommendations for a standardized pulmonary function report. An official American Thoracic Society  
21 technical statement. *American Journal of Respiratory and Critical Care Medicine* 196, 1463–1472.  
22 <https://doi.org/10.1164/rccm.201710-1981ST>

23 Dauphiné, D.C., Ferreccio, C., Guntur, S., Yuan, Y., Hammond, S.K., Balmes, J., Smith, A.H., Steinmaus, C.,  
24 2011. Lung function in adults following in utero and childhood exposure to arsenic in drinking water:  
25 Preliminary findings. *International Archives of Occupational and Environmental Health* 84, 591–600.  
26 <https://doi.org/10.1007/s00420-010-0591-6>

27 Farzan, S.F., Li, Z., Korrick, S.A., Spiegelman, D., Enelow, R., Nadeau, K., Baker, E.R., Karagas, M.R., 2016.  
28 Infant Infections and Respiratory Symptoms in Relation to Arsenic Exposure in a U.S. Cohort.  
29 *Environmental health perspectives*. <https://doi.org/http://dx.doi.org/10.1289/ehp.1409282>

30 Gilbert-Diamond, D., Emond, J.A., Baker, E.R., Korrick, S.A., Karagas, M.R., 2016. Relation between in  
31 Utero Arsenic Exposure and Birth Outcomes in a Cohort of Mothers and Their Newborns from New  
32 Hampshire. *Environmental Health Perspectives*. <https://doi.org/10.1289/ehp.1510065>

33 Hall, M., Gamble, M., Slavkovich, V., Liu, X., Levy, D., Cheng, Z., Geen, A. van, Yunus, M., Rahman, M.,  
34 Pilsner, J.R., Graziano, J., 2007. Determinants of arsenic metabolism: Blood arsenic metabolites, plasma  
35 folate, cobalamin, and homocysteine concentrations in maternal-newborn pairs. *Environmental Health*  
36 *Perspectives* 115, 1503–1509. <https://doi.org/10.1289/ehp.9906>

1 Harris, C., Crichton, S., Zivanovic, S., Lunt, A., Calvert, S., Marlow, N., Peacock, J.L., Greenough, A., 2018.  
2 Effect of dexamethasone exposure on the neonatal unit on the school age lung function of children born  
3 very prematurely. *PLoS ONE* 13, 1–13. <https://doi.org/10.1371/journal.pone.0200243>

4 Hsu, K.S., Goodale, B.C., Ely, K.H., Hampton, T.H., Stanton, B.A., Enelow, R.I., 2020. Single cell RNA-seq  
5 analysis reveals that prenatal arsenic exposure results in long-term, adverse effects on immune gene  
6 expression in response to Influenza A infection. *Toxicological Sciences* 176, 312–328.  
7 <https://doi.org/10.1093/toxsci/kfaa080>

8 IARC, 2012. Arsenic, Metals, Fibers and Dusts. A review of human carcinogens. IARC monographs on the  
9 evaluation of carcinogenic risks to humans. 100C, 527.

10 Karagas, M.R., Punshon, T., Sayarath, V., Jackson, B.P., Folt, C.L., Cottingham, K.L., 2016. Association of  
11 Rice and Rice-Product Consumption With Arsenic Exposure Early in Life. *JAMA Pediatrics* 03766, 1–8.  
12 <https://doi.org/10.1001/jamapediatrics.2016.0120>

13 Lange, P., Celli, B., Agustí, A., Jensen, G.B., Divo, M., Faner, R., Guerra, S., Marott, J.L., Martinez, F.D.,  
14 Martinez-Camblor, P., Meek, P., Owen, C.A., Petersen, H., Pinto-Plata, V., Schnohr, P., Sood, A., Soriano,  
15 J.B., Tesfaigzi, Y., Vestbo, J., 2015. Lung-function trajectories leading to chronic obstructive pulmonary  
16 disease. *New England Journal of Medicine* 373, 111–122. <https://doi.org/10.1056/NEJMoa1411532>

17 Lantz, R.C., Chau, B., Sarihan, P., Witten, M.L., Pivniouk, V.I., Chen, G.J., 2009. In Utero and Postnatal  
18 Exposure to Arsenic Alters Pulmonary Structure and Function. *Toxicology and Applied Pharmacology*  
19 235, 105–113. <https://doi.org/10.1016/j.taap.2008.11.012>

20 López-Carrillo, L., Hernández-Ramírez, R.U., Gandolfi, a J., Ornelas-Aguirre, J.M., Torres-Sánchez, L.,  
21 Cebrian, M.E., 2014. Arsenic methylation capacity is associated with breast cancer in northern Mexico.  
22 *Toxicology and applied pharmacology* 280, 53–9. <https://doi.org/10.1016/j.taap.2014.07.013>

23 Lubin, J.H., Colt, J.S., Camann, D., Davis, S., Cerhan, J.R., Severson, R.K., Bernstein, L., Hartge, P., 2004.  
24 Epidemiologic evaluation of measurement data in the presence of detection limits. *Environmental*  
25 *Health Perspectives* 112, 1691–1696. <https://doi.org/10.1289/ehp.7199>

26 Martinez-Pitre, P.J., Sabbula, B.R., Cascella, M., 2020. Restrictive Lung Disease. StatPearls Publishing.

27 Mazumder, D.N., 2007. Arsenic and non-malignant lung disease. *Journal of Environmental Science and*  
28 *Health - Part A Toxic/Hazardous Substances and Environmental Engineering* 42, 1859–1867.  
29 <https://doi.org/10.1080/10934520701566926>

30 McCarty, K.M., Chen, Y.C., Quamruzzaman, Q., Rahman, M., Mahiuddin, G., Hsueh, Y.M., Su, L., Smith,  
31 T., Ryan, L., Christiani, D.C., 2007. Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin  
32 lesions. *Environmental Health Perspectives* 115, 341–345. <https://doi.org/10.1289/ehp.9152>

33 Merkus, P.J.F.M., Ten Have-Opbroek, A.A.W., Quanjer, P.H., 1996. Human lung growth: A review.  
34 [https://doi.org/10.1002/\(SICI\)1099-0496\(199606\)21:6<383::AID-PPUL6>3.0.CO;2-M](https://doi.org/10.1002/(SICI)1099-0496(199606)21:6<383::AID-PPUL6>3.0.CO;2-M)

35 Miller, M.D., Marty, M.A., 2010. Impact of environmental chemicals on lung development.  
36 *Environmental Health Perspectives* 118, 1155–1164. <https://doi.org/10.1289/ehp.0901856>

1 Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P.,  
2 Grinten, C.P.M. van der, Gustafsson, P., Jensen, R., Johnson, D.C., MacIntyre, N., McKay, R., Navajas, D.,  
3 Pedersen, O.F., Pellegrino, R., Viegi, G., Wagner, J., 2005. Standardisation of spirometry. *European*  
4 *Respiratory Journal* 26, 319–338. <https://doi.org/10.1183/09031936.05.00034805>

5 Molin, M., Ulven, S.M., Meltzer, H.M., Alexander, J., 2015. Arsenic in the human food chain,  
6 biotransformation and toxicology – Review focusing on seafood arsenic. *Journal of Trace Elements in*  
7 *Medicine and Biology* 31, 249–259. <https://doi.org/10.1016/j.jtemb.2015.01.010>

8 Nachman, K.E., Punshon, T., Rardin, L., Signes-Pastor, A.J., Murray, C.J., Jackson, B.P., Guerinot, M.L.,  
9 Burke, T.A., Chen, C.Y., Ahsan, H., Argos, M., Cottingham, K.L., Cubadda, F., Ginsberg, G.L., Goodale, B.C.,  
10 Kurzius-spencer, M., Meharg, A.A., Miller, M.D., Nigra, A.E., Pendergrast, C.B., Raab, A., Reimer, K.,  
11 Scheckel, K.G., Schwerdtle, T., Taylor, V.F., Tokar, E.J., Warczak, T.M., Karagas, M.R., 2018. Opportunities  
12 and Challenges for Dietary Arsenic Intervention. *Environmental Health Perspectives* 126, 6–11.  
13 <https://doi.org/10.1289/EHP3997>

14 Navas-Acien, A., Francesconi, K.A., Silbergeld, E.K., Guallar, E., 2011. Seafood intake and urine  
15 concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population.  
16 *Environmental Research* 111, 110–118. <https://doi.org/10.1016/j.envres.2010.10.009>

17 NHDES, 2019. Arsenic in New Hampshire Well Water.

18 Niedzwiecki, M.M., Hall, M.N., Liu, X., Slavkovich, V., Ilievski, V., Levy, D., Alam, S., Siddique, A.B., Parvez,  
19 F., Graziano, J.H., Gamble, M.V., 2014. Interaction of plasma glutathione redox and folate deficiency on  
20 arsenic methylation capacity in Bangladeshi adults. *Free Radical Biology and Medicine* 73, 67–74.  
21 <https://doi.org/10.1016/j.freeradbiomed.2014.03.042>

22 Olivas-Calderón, E., Recio-Vega, R., Gandolfi, a.J., Lantz, R.C., González-Cortes, T., Gonzalez-De Alba, C.,  
23 Froines, J.R., Espinosa-Fematt, J.a., 2015. Lung inflammation biomarkers and lung function in children  
24 chronically exposed to arsenic. *Toxicology and Applied Pharmacology* 287, 161–167.  
25 <https://doi.org/10.1016/j.taap.2015.06.001>

26 Parvez, F., Chen, Y., Yunus, M., Olopade, M., Segers, S., Slavkovich, V., Argos, M., Hasan, R., Ahmed, A.,  
27 Islam, T., Akter, M.M., Graziano, J.H., Ahsan, H., 2013. Arsenic exposure and impaired lung function  
28 findings from a large population-based prospective cohort study. *American Journal of Respiratory and*  
29 *Critical Care Medicine* 188, 813–819. <https://doi.org/10.1164/rccm.201212-2282OC>

30 Postma, D.S., Bush, A., Van Den Berge, M., 2015. Risk factors and early origins of chronic obstructive  
31 pulmonary disease. [https://doi.org/10.1016/S0140-6736\(14\)60446-3](https://doi.org/10.1016/S0140-6736(14)60446-3)

32 Powers, M., Sanchez, T.R., Grau-Perez, M., Yeh, F., Francesconi, K.A., Goessler, W., George, C.M.,  
33 Heaney, C., Best, L.G., Umans, J.G., Brown, R.H., Navas-Acien, A., 2019. Low-moderate arsenic exposure  
34 and respiratory in American Indian communities in the Strong Heart Study. *Environmental Health: A*  
35 *Global Access Science Source* 18, 1–12. <https://doi.org/10.1186/s12940-019-0539-6>

36 Rahman, A., Vahter, M., Ekström, E.-C., Persson, L.-Å., 2011. Arsenic exposure in pregnancy increases  
37 the risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. *Environmental*  
38 *health perspectives* 119, 719–24. <https://doi.org/10.1289/ehp.1002265>

1 Ramsey, K.A., Larcombe, A.N., Sly, P.D., Zosky, G.R., 2013. In utero exposure to low dose arsenic via  
2 drinking water impairs early life lung mechanics in mice. *BMC Pharmacology and Toxicology* 14, 1.  
3 <https://doi.org/10.1186/2050-6511-14-13>

4 Raqib, R., Ahmed, S., Sultana, R., Wagatsuma, Y., Mondal, D., Hoque, A.M., Nermell, B., Yunus, M., Roy,  
5 S., Persson, L.A., Arifeen, S.E., Moore, S., Vahter, M., 2009. Effects of in utero arsenic exposure on child  
6 immunity and morbidity in rural Bangladesh. *Toxicology Letters*.  
7 <https://doi.org/10.1016/j.toxlet.2009.01.001>

8 R Code Team, 2015. A language and environment for statistical computing.

9 Recio-Vega, R., Gonzalez-Cortes, T., Olivas-Calderon, E., Lantz, R.C., Gandolfi, A.J., Alba, C.G.-D., 2015. In  
10 utero and early childhood exposure to arsenic decreases lung function in children. *Journal of Applied*  
11 *Toxicology* 35, 358–366. <https://doi.org/10.1002/jat.3023>

12 Sanchez, T.R., Perzanowski, M., Graziano, J.H., 2016. Inorganic arsenic and respiratory health, from early  
13 life exposure to sex-specific effects: A systematic review. *Environmental Research* 147, 537–555.  
14 <https://doi.org/10.1016/j.envres.2016.02.009>

15 Sanchez, T.R., Powers, M., Perzanowski, M., George, C.M., Graziano, J.H., Navas-Acien, A., 2018. A Meta-  
16 analysis of Arsenic Exposure and Lung Function: Is There Evidence of Restrictive or Obstructive Lung  
17 Disease? <https://doi.org/10.1007/s40572-018-0192-1>

18 Shen, J., Liu, J., Xie, Y., Diwan, B.A., Waalkes, M.P., 2007. Fetal onset of aberrant gene expression  
19 relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic  
20 exposure. *Toxicological Sciences*. <https://doi.org/10.1093/toxsci/kfl151>

21 Shih, Y.H., Argos, M., Turyk, M.E., 2019. Urinary arsenic concentration, airway inflammation, and lung  
22 function in the U.S. adult population. *Environmental Research* 175, 308–315.  
23 <https://doi.org/10.1016/j.envres.2019.05.031>

24 Signes-Pastor, A.J., Carey, M., Vioque, J., Navarrete-Muñoz, E.M., Rodríguez-Dehli, C., Tardón, A.,  
25 Begoña-Zubero, M., Santa-Marina, L., Vrijheid, M., Casas, M., Llop, S., Gonzalez-Palacios, S., Meharg,  
26 A.A., 2017b. Urinary Arsenic Speciation in Children and Pregnant Women from Spain. *Exposure and*  
27 *Health* 9, 105–111. <https://doi.org/10.1007/s12403-016-0225-7>

28 Signes-Pastor, A.J., Cottingham, K.L., Carey, M., Sayarath, V., Palys, T., Meharg, A.A., Folt, C.L.C.L.,  
29 Karagas, M.R., Kathryn, L.C., 2018. Infants ' dietary arsenic exposure during transition to solid food.  
30 *Scientific Reports* 8, 2–9. <https://doi.org/10.1038/s41598-018-25372-1>

31 Signes-Pastor, A.J., Gutiérrez-González, E., García-Villarino, M., Rodríguez-Cabrera, F.D., López-Moreno,  
32 J.J., Varea-Jiménez, E., Pastor-Barriuso, R., Pollán, M., Navas-Acien, A., Pérez-Gómez, B., Karagas, M.R.,  
33 2021. Toenails as a biomarker of exposure to arsenic: A review. *Environmental Research* 110286.  
34 <https://doi.org/10.1016/j.envres.2020.110286>

35 Signes-Pastor, A.J., Punshon, T., Cottingham, K.L., Jackson, B.P., Sayarath, V., Gilbert-Diamond, D.,  
36 Korrick, S., Karagas, M.R., 2020. Arsenic Exposure in Relation to Apple Consumption Among Infants in

the New Hampshire Birth Cohort Study. *Exposure and Health*. <https://doi.org/10.1007/s12403-020-00356-7>

Signes-Pastor, A.J., Vioque, J., Navarrete-Muñoz, E.M., Carey, M., García de la Hera, M., Sunyer, J., Casas, M., Riaño-Galán, I., Tardón, A., Llop, S., Amorós, R., Karagas, M.R., Meharg, A.A., 2017a. Concentrations of urinary arsenic species in relation to rice and seafood consumption among children living in Spain. *Environmental Research* 159, 69–75. <https://doi.org/10.1016/j.envres.2017.07.046>

Signes-Pastor, A.J., Vioque, J., Navarrete-Muñoz, E.M., Carey, M., García-Villarino, M., Fernández-Somoano, A., Tardón, A., Santa-Marina, L., Irizar, A., Casas, M., Guxens, M., Llop, S., Soler-Blasco, R., García-de-la-Hera, M., Karagas, M.R., Meharg, A.A., 2019. Inorganic arsenic exposure and neuropsychological development of children of 4–5 years of age living in Spain. *Environmental Research* 174, 135–142. <https://doi.org/10.1016/j.envres.2019.04.028>

Smith, A.H., Marshall, G., Yuan, Y., Ferreccio, C., Liaw, J., Ehrenstein, O. von, Steinmaus, C., Bates, M.N., Selvin, S., 2006. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. *Environmental Health Perspectives* 114, 1293–1296. <https://doi.org/10.1289/ehp.8832>

Smith, A.H., Marshall, G., Yuan, Y., Liaw, J., Ferreccio, C., Steinmaus, C., 2011. Evidence from Chile that arsenic in drinking water may increase mortality from pulmonary tuberculosis. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwq383>

Smith, A.H., Yunus, M., Khan, A.F., Ercumen, A., Yuan, Y., Smith, M.H., Liaw, J., Balmes, J., Von Ehrenstein, O., Raqib, R., Kalman, D., Alam, D.S., Streatfield, P.K., Steinmaus, C., 2013. Chronic respiratory symptoms in children following in utero and early life exposure to arsenic in drinking water in Bangladesh. *International Journal of Epidemiology* 42, 1077–1086. <https://doi.org/10.1093/ije/dyt120>

Steinmaus, C., Bates, M.N., Yuan, Y., Kalman, D., Atallah, R., Rey, O.A., Biggs, M.L., Hopenhayn, C., Moore, L.E., Hoang, B.K., Smith, A.H., 2006. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. *Journal of Occupational and Environmental Medicine*. <https://doi.org/10.1097/01.jom.0000200982.28276.70>

Steinmaus, C., Ferreccio, C., Acevedo, J., Balmes, J.R., Liaw, J., Troncoso, P., Dauphin, D.C., Nardone, A., Smith, A.H., 2016. High risks of lung disease associated with early-life and moderate lifetime arsenic exposure in northern Chile. *Toxicology and Applied Pharmacology* 313, 10–15. <https://doi.org/10.1016/j.taap.2016.10.006>

Stick, S.M., Burton, P.R., Gurrin, L., Sly, P.D., LeSouëf, P.N., 1996. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. *Lancet*. [https://doi.org/10.1016/S0140-6736\(96\)04446-7](https://doi.org/10.1016/S0140-6736(96)04446-7)

Tseng, C.-h.H., 2009. A review on environmental factors regulating arsenic methylation in humans. *Toxicology and Applied Pharmacology* 235, 338–350. <https://doi.org/10.1016/j.taap.2008.12.016>

US EPA, 2012. US Environmental Protection Agency: 2012 Edition of the Drinking Water Standards and Health Advisories. 2012 Edition of the Drinking Water Standards and Health Advisories 2–6.

1 Vahter, M., 2002. Mechanisms of arsenic biotransformation. *Toxicology* 181-182, 211–217.  
2 [https://doi.org/10.1016/S0300-483X\(02\)00285-8](https://doi.org/10.1016/S0300-483X(02)00285-8)

3 Von Ehrenstein, O.S., Mazumder, D.N., Yuan, Y., Samanta, S., Balmes, J., Sil, A., Ghosh, N., Hira-Smith,  
4 M., Haque, R., Purushothamam, R., Lahiri, S., Das, S., Smith, A.H., 2005. Decrements in lung function  
5 related to arsenic in drinking water in West Bengal, India. *American Journal of Epidemiology* 162, 533–  
6 541. <https://doi.org/10.1093/aje/kwi236>

7 WHO, 2011. WHO guidelines for drinking-water quality. *WHO chronicle* 38, 104–108.  
8 [https://doi.org/10.1016/S1462-0758\(00\)00006-6](https://doi.org/10.1016/S1462-0758(00)00006-6)

9 Yu, R.C., Hsu, K.H., Chen, C.J., Froines, J.R., 2000. Arsenic methylation capacity and skin cancer. *Cancer*  
10 *Epidemiology Biomarkers and Prevention*.  
11

1 **Table 1:** Selected characteristics of study mothers and children.


Variables	Original sample (n = 419)	Final sample (n = 358)*	Excluded sample (n = 61) <sup>u</sup>
<b>Maternal characteristics</b>			
Gestational age (weeks)	39 (29, 38.4 – 40.0, 42)	39.0 (30.9, 38.4 – 40.0, 42.0)	39.1 (29.0, 38.3 – 40.0, 42.0)
Age of enrollment	30.8 (18.9, 28.1 – 33.6, 44.3)	30.7 (19.1, 28.1 – 33.4, 44.3)	31.9 (18.9, 28.6 – 34.4, 41.8)
Maternal BMI	24.8 (16.6, 21.9 – 28.8, 48.3)	24.7 (16.6, 21.8 – 28.3, 48.3)	26.5 (18.3, 22.7 – 30.7, 47.3)
Maternal education:			
Less than 11 <sup>th</sup> grade or high school graduate or equivalent	35 (8.8%)	31 (8.7%)	4 (10.5%)
Junior college graduate or some college or technical school	83 (21.0%)	71 (19.8%)	12 (31.6%)
College graduate	162 (40.9%)	152 (42.5%)	10 (26.3%)
Any postgraduate schooling	116 (29.3%)	104 (29.1%)	12 (31.6%)
Parity:			
0	164 (39.5%)	144 (40.7%)	20 (32.8%)
1	157 (37.8%)	132 (37.3%)	25 (41.0%)
>1	94 (22.7%)	78 (22.0%)	16 (26.2%)
Smoking status:			
Never smoker	351 (90.2%)	322 (89.9%)	29 (93.5%)
Former smoker	19 (4.9%)	18 (5.0%)	1 (3.2%)
Current smoke	19 (4.9%)	18 (5.0%)	1 (3.2%)
Urinary arsenic (µg/L):			
iAs (iAsIII + iAsV)	0.26 (0.02, 0.07 – 0.48, 10.51)	0.25 (0.02, 0.07 – 0.48, 10.51)	0.39 (0.02, 0.24 – 0.65, 6.00)
MMA	0.32 (0.01, 0.13 – 0.55, 3.67)	0.30 (0.01, 0.13 – 0.54, 3.67)	0.45 (0.02, 0.23 – 0.71, 2.96)
DMA	3.03 (0.15, 1.39 – 5.28, 152.7)	2.89 (0.15, 1.30 – 5.12, 30.84)	3.84 (0.16, 2.29 – 6.41, 152.7)
AsB	0.88 (0.01, 0.13 – 5.67, 693.4)	0.80 (0.01, 0.13 – 5.24, 693.4)	2.03 (0.02, 0.44 – 8.80, 259.9)
ΣAs	3.76 (0.20, 1.66 – 6.62, 154.8)	3.64 (0.25, 1.51 – 6.17, 38.30)	4.57 (0.20, 3.16 – 7.59, 154.8)
Specific gravity	1.013 (1.001, 1.006 – 1.019, 1.037)	1.012 (1.001, 1.006 – 1.019, 1.037)	1.017 (1.004, 1.012 – 1.022, 1.028)
Marital status			
Married	346 (87.4%)	314 (87.7%)	32 (84.2%)
Single	40 (10.1%)	36 (10.1%)	4 (10.5%)
Divorced	10 (2.5%)	8 (2.2%)	2 (5.3%)
<b>Children's characteristics at spirometry test</b>			
Male/female	199 (47.5%)/220 (52.5%)	167 (46.6%)/191 (53.4%)	32 (52.5%)/29 (47.5%)
Age (years)	7.4 (4.9, 7.1 – 7.9, 9.5)	7.4 (4.9, 7.0 – 7.9, 9.5)	7.6 (5.4, 7.1 – 8.1, 9.3)
Height (cm)	124.7 (104.6, 121.1 – 129.1, 142.8)	125.0 (104.6, 121.0 – 129.0, 152.6)	123.7 (114.5, 121.9 – 130.6, 142.5)
Weight (kg)	25.7 (13.0, 22.7 – 29.0, 58.0)	25.6 (13.0, 22.7 – 29.0, 60.4)	26.0 (19.3, 23.0 – 28.8, 39.7)
FEV1/FVC	0.9 (0.6, 0.8 – 0.9, 1.0)	0.9 (0.6, 0.8 – 0.9, 1.0)	0.9 (0.6, 0.8 – 0.9, 1.0)
FVC z-score	-0.5 (-6.3, -1.2 – 0.0, 2.9)	-0.5 (-3.2, -1.2 – 0.1, 3.0)	-0.5 (-5.6, -1.1 – 0.0, 1.0)
FEV1 z-score	0.4 (-5.5, -0.4 – 1.0, 4.5)	0.4 (-2.5, -0.4 – 1.0, 4.6)	0.4 (-5.3, -0.4 – 1.0, 2.6)
FEF25-75 z-score	-0.3 (-8.4, -2.0 – 1.2, 8.3)	-0.2 (-8.4, -2.0 – 1.4, 8.3)	-0.8 (-6.6, -2.0 – 0.7, 4.9)
<b>Other characteristics</b>			
Tap water As (µg/L):			
<1	198 (50.0%)	175 (50%)	23 (50%)
1-10	129 (32.6%)	113 (32.3%)	16 (34.8%)
>10	69 (17.4%)	62 (17.7%)	7 (15.2%)



1 <sup>†</sup>Participants after excluding those with missing values in any spirometry parameters of interest, spirometry values out of acceptable range,  
2 missing specific gravity, without maternal urinary arsenic species concentration, maternal smoking status, children's sex, age, and height.  
3 <sup>‡</sup>Excluded participants. Continuous values are reported as median (minimum, interquartile range, maximum), and categorical values as relative  
4 and absolute frequencies. The total count of missing values in the original sample is 5 in maternal BMI, 23 in education, 4 in parity, 30 in  
5 smoking status, 24 in urinary arsenic speciation and specific gravity, 23 in marital status, 3 in child's height, 1 in weight, 1 in FEV1/FVC, 1 in FVC  
6 z-score, 3 in FEV1 z-score, 8 in FEF25-75 z-score, and 23 in tap water arsenic. The total count of missing values for the final sample is 1 in  
7 maternal BMI, 4 in parity, and 8 in tap water.

8


**Figure 1:** Association between maternal urinary arsenic species concentration and standardized z-scores from children’s spirometry.




Oval = overall ( $n = 358$ ); LP = low primary methylation index (PMI <median;  $n = 179$ ); HP = high primary methylation index (PMI >median;  $n = 179$ ); LS = low secondary methylation index (SMI <median;  $n = 179$ ); HS = high secondary methylation index (SMI >median;  $n = 179$ ). Linear regression models with spirometry parameters standardized z-score as dependent variables and  $\log_2$ -transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for maternal smoking status, children's age, sex, and height. Notice that the scale of the y-axis vary in order to facilitate the visualization of the estimates in each plot.

**Supplemental Information**

**Figure S1:** Steps to create the final study samples of 385 participants.




**Figure S2:** Association between maternal urinary arsenic speciation and standardized z-scores from children’s spirometry – sensitivity analysis.



Oval = overall ( $n = 357$ ); LP = low primary methylation index (PMI <median;  $n = 179$ ); HP = high primary methylation index (PMI >median;  $n = 178$ ); LS = low secondary methylation index (SMI <median;  $n = 179$ ); HS = high secondary methylation index (SMI >median;  $n = 178$ ). Linear regression models with spirometry parameters standardized z-score as dependent variables and  $\log_2$ -transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for maternal age of enrollment and smoking status, and children's age, sex, height, and weight. Notice that the scale of the y-axis vary in order to facilitate the visualization of the estimates in each plot.

1 **Figure S3:** Association between maternal urinary arsenic speciation and standardized z-scores from children's spirometry stratified by sex.

2



3

4 Oval = overall ( $n$  boys = 167 and  $n$  girls = 191); LP = low primary methylation index (PMI < median;  $n$  boys = 84 and  $n$  girls = 96); HP = high primary methylation index (PMI > median;  $n$  boys = 83 and  $n$  girls = 95); LS = low secondary methylation index (SMI < median;  $n$  boys = 84 and  $n$  girls = 96); HS = high secondary methylation index (SMI > median;  $n$  boys = 83 and  $n$  girls = 95). Linear regression models with spirometry parameters standardized z-score as dependent variables and  $\log_2$ -transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for maternal smoking status, children's age and height. Notice that the scale of the y-axis vary in order to facilitate the visualization of the estimates in each plot.

5

6

7

**Table S1:** Association between maternal urinary arsenic species concentration and children's spirometry FEV1/FVC overall and according to maternal methylation capacity as described in **Figure 1**.

Spirometry	Model	n	log <sub>2</sub> As	Estimate	p-value	95% CI
FEV1/FVC	Overall	358	iAs	0.003	0.269	-0.002, 0.007
			MMA	0.001	0.699	-0.003, 0.004
			DMA	0.001	0.650	-0.004, 0.006
			ΣAs	0.002	0.478	-0.003, 0.007
	Low PMI	179	iAs	0.001	0.667	-0.005, 0.007
			MMA	0.000	0.965	-0.005, 0.005
			DMA	-0.001	0.814	-0.007, 0.006
			ΣAs	0.000	0.989	-0.007, 0.007
	High PMI	179	iAs	0.003	0.345	-0.004, 0.011
			MMA	0.003	0.440	-0.005, 0.012
			DMA	0.004	0.337	-0.005, 0.014
			ΣAs	0.005	0.287	-0.004, 0.015
	Low SMI	179	iAs	0.005	0.202	-0.002, 0.011
			MMA	0.003	0.475	-0.006, 0.012
			DMA	0.003	0.516	-0.006, 0.011
			ΣAs	0.004	0.318	-0.004, 0.013
	High SMI	179	iAs	0.000	0.942	-0.007, 0.007
			MMA	-0.001	0.584	-0.006, 0.004
			DMA	0.000	0.891	-0.007, 0.006
			ΣAs	0.000	0.911	-0.007, 0.006

Linear regression models with FEV1/FVC as dependent variable and log<sub>2</sub>-transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for maternal smoking status, children's age, sex, and height.

1 **Table S2:** Association between maternal urinary arsenic species concentration and standardized z-scores  
2 from children's spirometry overall and restricted to maternal never smoker.

Model	Spirometry	log <sub>2</sub> As	n <sup>†</sup>	Estimate	p-value	95% CI	n <sup>‡</sup>	Estimate	p-value	95% CI	Interaction <sup>Δ</sup>
											p-value
Oval	FEV1 z-score	iAs	35			-0.16, -	32			-0.19, -	
			8	-0.09	0.010	0.02	2	-0.11	0.010	0.04	0.827
		MMA	35			-0.12, -	32			-0.14, -	
			8	-0.07	0.030	0.01	2	-0.08	0.010	0.02	0.412
		DMA	35			-0.17, -	32			-0.19, -	
			8	-0.08	0.040	0.01	2	-0.10	0.020	0.02	0.564
	FVC z-score	ΣAs	35			-0.18, -	32			-0.20, -	
			8	-0.10	0.020	0.02	2	-0.11	0.010	0.03	0.470
		iAs	35			-0.12, -	32			-0.15, -	
			8	-0.06	0.040	0.01	2	-0.09	0.010	0.02	0.933
		MMA	35			-0.11, -	32			-0.11, -	
			8	-0.05	0.060	-0.10, 0.00	2	-0.06	0.020	0.01	0.402
	FEF25-75 z score	DMA	35			-0.14, -	32			-0.16, -	
			8	-0.07	0.040	0.01	2	-0.09	0.010	0.02	0.623
		ΣAs	35			-0.14, -	32			-0.16, -	
			8	-0.08	0.030	0.01	2	-0.09	0.010	0.02	0.563
		iAs	35				32				
			8	-0.09	0.330	-0.26, 0.09	2	-0.11	0.220	-0.30, 0.07	0.903
LP	FEV1 z-score	MMA	35				32				
			8	-0.07	0.340	-0.21, 0.07	2	-0.09	0.220	-0.24, 0.05	0.498
		DMA	35				32				
			8	-0.07	0.460	-0.26, 0.12	2	-0.11	0.260	-0.31, 0.09	0.281
		ΣAs	35				32				
			8	-0.08	0.430	-0.27, 0.12	2	-0.12	0.240	-0.32, 0.08	0.304
	FVC z-score	iAs	17				16				
			9	-0.09	0.080	-0.19, 0.01	1	-0.09	0.097	-0.19, 0.02	0.748
		MMA	17				16				
			9	-0.05	0.220	-0.13, 0.03	1	-0.06	0.144	-0.15, 0.02	0.481
		DMA	17				16				
			9	-0.07	0.200	-0.18, 0.04	1	-0.09	0.123	-0.21, 0.03	0.560
	FEF25-75 z score	ΣAs	17				16				
			9	-0.08	0.130	-0.20, 0.03	1	-0.10	0.105	-0.22, 0.02	0.463
		iAs	17				16				
			9	-0.05	0.200	-0.13, 0.03	1	-0.06	0.194	-0.15, 0.03	0.846
		MMA	17				16				
			9	-0.02	0.480	-0.09, 0.04	1	-0.04	0.325	-0.10, 0.04	0.508
HP	FEV1 z-score	DMA	17				16				
			9	-0.06	0.230	-0.15, 0.04	1	-0.08	0.134	-0.17, 0.02	0.663
		ΣAs	17				16				
			9	-0.06	0.190	-0.15, 0.03	1	-0.07	0.139	-0.17, 0.02	0.581
		iAs	17				16				
			9	-0.07	0.530	-0.30, 0.16	1	-0.11	0.366	-0.35, 0.13	0.927
	FVC z-score	MMA	17				16				
			9	-0.06	0.530	-0.24, 0.12	1	-0.10	0.316	-0.29, 0.09	0.710
		DMA	17				16				
			9	-0.11	0.410	-0.37, 0.15	1	-0.16	0.238	-0.44, 0.11	0.586
		ΣAs	17				16				
			9	-0.11	0.410	-0.36, 0.15	1	-0.16	0.236	-0.43, 0.11	0.581
	FEF25-75 z score	iAs	17				16			-0.27, -	
			9	-0.10	0.070	-0.21, 0.01	1	-0.15	0.011	0.04	0.915
		MMA	17				16			-0.30, -	
			9	-0.10	0.130	-0.23, 0.03	1	-0.16	0.023	0.02	0.641
		DMA	17				16				
			9	-0.08	0.240	-0.22, 0.06	1	-0.11	0.141	-0.26, 0.04	0.940
HP	FEV1 z-score	ΣAs	17				16				
			9	-0.10	0.180	-0.25, 0.05	1	-0.13	0.083	-0.29, 0.02	0.919
		iAs	17				16			-0.22, -	
			9	-0.09	0.060	-0.17, 0.00	1	-0.13	0.007	0.04	0.945
		MMA	17				16			-0.25, -	
			9	-0.09	0.120	-0.19, 0.02	1	-0.14	0.015	0.03	0.646
	FVC z-score	DMA	17				16				
			9	-0.07	0.240	-0.18, 0.05	1	-0.10	0.113	-0.21, 0.02	0.976
		ΣAs	17				16				
			9	-0.08	0.170	-0.20, 0.04	1	-0.12	0.064	-0.24, 0.01	0.981
		iAs	17				16				
			9	-0.11	0.410	-0.38, 0.16	1	-0.13	0.377	-0.42, 0.16	0.753

LS	FEV1 z-score	MMA	17 9	-0.06	0.690	-0.38, 0.25	16 1	-0.07	0.707	-0.41, 0.28	0.825
		DMA	17 9	0.03	0.880	-0.31, 0.36	16 1	-0.01	0.966	-0.36, 0.35	0.485
		ΣAs	17 9	0.02	0.930	-0.33, 0.37	16 1	-0.02	0.915	-0.39, 0.35	0.542
		iAs	17 9	-0.16	0.000	-0.26, -0.05	16 1	-0.16	0.004	-0.27, -0.05	0.526
		MMA	17 9	-0.20	0.010	-0.33, -0.06	16 1	-0.21	0.005	-0.35, -0.06	0.309
		DMA	17 9	-0.10	0.120	-0.23, 0.03	16 1	-0.11	0.109	-0.24, 0.03	0.202
		ΣAs	17 9	-0.14	0.040	-0.28, -0.01	16 1	-0.14	0.050	-0.28, 0.00	0.140
		iAs	17 9	-0.11	0.010	-0.19, -0.03	16 1	-0.12	0.011	-0.21, -0.03	0.721
	FVC z-score	MMA	17 9	-0.18	0.000	-0.29, -0.07	16 1	-0.18	0.002	-0.30, -0.07	0.356
		DMA	17 9	-0.10	0.060	-0.21, 0.00	16 1	-0.10	0.075	-0.21, 0.01	0.216
		ΣAs	17 9	-0.13	0.020	-0.23, -0.02	16 1	-0.12	0.040	-0.23, -0.01	0.175
		iAs	17 9	-0.11	0.380	-0.35, 0.14	16 1	-0.14	0.280	-0.41, 0.12	0.094
	FEF25-75 z score	MMA	17 9	-0.04	0.800	-0.37, 0.28	16 1	-0.04	0.826	-0.37, 0.30	0.051
		DMA	17 9	0.04	0.820	-0.27, 0.34	16 1	0.02	0.910	-0.30, 0.33	0.022
		ΣAs	17 9	0.01	0.970	-0.31, 0.32	16 1	-0.01	0.941	-0.34, 0.32	0.021
		iAs	17 9	-0.05	0.450	-0.17, 0.08	16 1	-0.08	0.218	-0.22, 0.05	0.289
	FEV1 z-score	MMA	17 9	-0.06	0.200	-0.14, 0.03	16 1	-0.08	0.086	-0.17, 0.01	0.676
		DMA	17 9	-0.07	0.180	-0.18, 0.04	16 1	-0.10	0.086	-0.22, 0.01	0.603
		ΣAs	17 9	-0.07	0.190	-0.18, 0.04	16 1	-0.10	0.088	-0.22, 0.02	0.566
		iAs	17 9	-0.04	0.440	-0.14, 0.06	16 1	-0.08	0.133	-0.19, 0.03	0.249
HS	FVC z-score	MMA	17 9	-0.03	0.350	-0.10, 0.04	16 1	-0.06	0.097	-0.14, 0.01	0.796
		DMA	17 9	-0.05	0.240	-0.14, 0.04	16 1	-0.09	0.069	-0.18, 0.01	0.560
		ΣAs	17 9	-0.05	0.250	-0.14, 0.04	16 1	-0.09	0.070	-0.18, 0.01	0.528
		iAs	17 9	-0.14	0.330	-0.43, 0.14	16 1	-0.15	0.347	-0.47, 0.17	0.073
	FEF25-75 z score	MMA	17 9	-0.15	0.130	-0.35, 0.04	16 1	-0.19	0.088	-0.40, 0.03	0.389
		DMA	17 9	-0.15	0.250	-0.40, 0.10	16 1	-0.21	0.128	-0.48, 0.06	0.640
		ΣAs	17 9	-0.15	0.250	-0.41, 0.11	16 1	-0.21	0.139	-0.48, 0.07	0.563
		iAs	17 9	-0.14	0.330	-0.43, 0.14	16 1	-0.15	0.347	-0.47, 0.17	0.073
	FEV1 z-score	MMA	17 9	-0.06	0.200	-0.14, 0.03	16 1	-0.08	0.086	-0.17, 0.01	0.676
		DMA	17 9	-0.07	0.180	-0.18, 0.04	16 1	-0.10	0.086	-0.22, 0.01	0.603
		ΣAs	17 9	-0.07	0.190	-0.18, 0.04	16 1	-0.10	0.088	-0.22, 0.02	0.566
		iAs	17 9	-0.04	0.440	-0.14, 0.06	16 1	-0.08	0.133	-0.19, 0.03	0.249

Oval = overall; LP = low primary methylation index (PMI <median); HP = high primary methylation index (PMI >median); LS = low secondary methylation index (SMI <median); HS = high secondary methylation index (SMI >median). \*Linear regression models with spirometry parameters standardized z-score as dependent variables and log<sub>2</sub>-transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for maternal smoking status, children's age, sex, and height. †Linear regression models with spirometry parameters standardized z-score as dependent variables and log<sub>2</sub>-transformed maternal urinary arsenic species concentrations specific gravity corrected as independent variables adjusted for children's age, sex, and height. ‡P-value interaction term children's sex \* maternal urinary arsenic species concentrations from the linear regression models adjusted for maternal smoking status, children's age, sex, and height.